Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$901K Sell
13,384
-34
-0.3% -$2.27K 0.09% 358
2026
Q1
$843K Buy
+13,418
New +$934K 0.08% 355
2025
Q4
Sell
-11,645
Closed -$784K 538
2025
Q3
$784K Buy
+11,645
New +$922K 0.12% 314
2025
Q1
Sell
-6,223
Closed -$484K 462
2024
Q4
$484K Sell
6,223
-34,301
-85% -$2.54M 0.14% 253
2024
Q3
$2.72M Buy
+40,524
New +$3.33M 0.88% 4
2023
Q2
Sell
-3,322
Closed -$386K 409
2023
Q1
$386K Buy
+3,322
New +$372K 0.23% 205

Other funds holding DXCM

Oak Thistle LLC's DXCM Position: Q2 2026 in Review

Oak Thistle LLC reduced its DexCom (DXCM) stake by 0.25% in Q2 2026, selling an estimated $2.27K and leaving 13,384 shares worth $901K. The position accounts for 0.09% of the portfolio, ranked #358.

Oak Thistle LLC first reported a position in DXCM in Q1 2023 and has held it in 6 quarters since. The position peaked at $2.72M in Q3 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Oak Thistle LLC held 13,384 shares of DexCom worth $901K as of Q2 2026.
  • Oak Thistle LLC sold 34 DexCom shares in Q2 2026, an estimated $2.27K.
  • DexCom made up 0.09% of Oak Thistle LLC's portfolio in Q2 2026, its #358 holding.
  • Oak Thistle LLC first reported a position in DexCom in Q1 2023 and has held it in 6 quarters since.
  • Oak Thistle LLC's DexCom position peaked at $2.72M in Q3 2024.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Oak Thistle LLC's 13F filing for Q2 2026, filed 21 Jul 2026.